Inderjit Mehmi

6PUBLICATIONS
67CO-AUTHORS
NanomedicineMedical devicesPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 18, 2026
Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study.

|Feb 16, 2026
LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial.

O Hamid, V Ekström-Rydén, I Mehmi

|Jan 10, 2026
Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.

Juan Alban, R Christopher Bowen, David A Reichstein

|Jan 09, 2025
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.

Sylvia M Lee, Omid Hamid, Robert Jotte

|Dec 08, 2021
Immunotherapy of cancer in the era of checkpoint inhibitor.

Inderjit Mehmi, Omid Hamid

|Nov 11, 2021
Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer.

Jane C Figueiredo, Noah M Merin, Omid Hamid

Pageof 1

Frequent Collaborators

4 joint publications

Omid Hamid

2 joint publications

Sunandana Chandra

1 joint publications

V Ekström-Rydén

1 joint publications

D Wang